Ετικέτες

Τρίτη 4 Δεκεμβρίου 2018

Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia

doctordrawingblood-article.__v20093246.j

A clinical trial showed that ibrutinib plus rituximab is superior to standard treatment for patients age 70 and younger with untreated chronic lymphocytic leukemia (CLL). Findings were announced at the American Society of Hematology annual meeting.



https://ift.tt/2BRZezr

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αναζήτηση αυτού του ιστολογίου